Journal
JOURNAL OF CLINICAL NEUROSCIENCE
Volume 21, Issue 3, Pages 507-508Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2013.04.021
Keywords
Hypersexuality; Impulse control disorders; Parkinson's disease; Rasagiline
Categories
Ask authors/readers for more resources
Impulse control disorders (ICD) are increasingly recognized in patients with Parkinson's disease (PD), particularly when treated with commonly used dopamine agonists such as pramipexole and ropinirole [1-5]. Less evident is the possible association between monoamine oxidase inhibitors type B (MAO-B) and the development of ICD [5]. Rasagiline is a second generation MAO-B I inducing moderate symptomatic and possibly disease modifying benefits with apparently good tolerability and safety profile in PD patients. Rasagiline is effective and well tolerated in PD as a monotherapy or in combination with levodopa [6]. Here, we report a patient with PD who developed ICD when treated de novo with MAO-B inhibitors. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available